ANI Pharmaceuticals (ANIP) counsel sells 500 shares under 10b5-1 plan
Rhea-AI Filing Summary
ANI Pharmaceuticals Inc. reported that senior vice president, general counsel and secretary Meredith Cook completed an open-market sale of 500 shares of common stock on July 13, 2026 at $81.84 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on September 15, 2025, and Cook now directly holds 77,390 shares of ANI Pharmaceuticals common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 500 shares ($40,920)
Net Sell
1 txn
Insider
Cook Meredith
Role
SR. VP, GENERAL COUNSEL & SEC.
Sold
500 shs ($41K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 500 | $81.84 | $41K |
Holdings After Transaction:
Common Stock — 77,390 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Shares sold: 500 shares
Sale price: $81.84 per share
Shares owned after transaction: 77,390 shares
+2 more
5 metrics
Shares sold
500 shares
Open-market sale of ANI Pharmaceuticals common stock on July 13, 2026
Sale price
$81.84 per share
Price received per share for the 500 shares of common stock sold
Shares owned after transaction
77,390 shares
Direct common stock holdings of Meredith Cook following the sale
Net buy/sell shares
-500 shares
Net insider trading activity reported in this Form 4
10b5-1 plan adoption date
September 15, 2025
Date the Rule 10b5-1 trading plan governing this sale was adopted
Key Terms
Rule 10b5-1 trading plan, open-market sale, Form 4
3 terms
Rule 10b5-1 trading plan regulatory
"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale market
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Form 4 regulatory
"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What is Meredith Cook’s position at ANI Pharmaceuticals (ANIP)?
Meredith Cook is an officer of ANI Pharmaceuticals, serving as Senior Vice President, General Counsel and Secretary. She is not listed as a director or a ten percent owner in this Form 4 filing.
Was the ANI Pharmaceuticals (ANIP) insider sale made under a Rule 10b5-1 plan?
Yes. The filing states the sale was effected pursuant to a Rule 10b5-1 trading plan that Meredith Cook adopted on September 15, 2025. Such plans allow pre-scheduled trading according to predetermined instructions.
Did the ANI Pharmaceuticals (ANIP) Form 4 include any option exercises or derivative transactions?
No. The Form 4 reports only a single open-market sale of 500 shares of common stock. The derivative transaction count and exercise share count are both reported as zero, and the derivative summary section is empty.